Cerpegin-derived furo[3,4-c]pyridine-3,4(1H,5H)-diones enhance cellular response to interferons by de novo pyrimidine biosynthesis inhibition

Simon Hayek, Nicolas Pietrancosta, Anna Hovhannisyan, Rodolphe Alves de Sousa, Nassima Bekaddour, Laura Ermellino, Enzo Tramontano, Stéphanie Arnould, Claude Sardet, Julien Dairou, et al.

► To cite this version:

Simon Hayek, Nicolas Pietrancosta, Anna Hovhannisyan, Rodolphe Alves de Sousa, Nassima Bekaddour, et al.. Cerpegin-derived furo[3,4-c]pyridine-3,4(1H,5H)-diones enhance cellular response to interferons by de novo pyrimidine biosynthesis inhibition. *European Journal of Medicinal Chemistry*, 2020, 186, pp.111855. 10.1016/j.ejmech.2019.111855 . hal-02372490

HAL Id: hal-02372490

<https://hal.science/hal-02372490>

Submitted on 25 Jan 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Cerpegin-derived furo[3,4-*c*]pyridine-3,4(1*H*,5*H*)-diones enhance cellular response to interferons by de novo pyrimidine biosynthesis inhibition

Simon Hayek¹, Nicolas Pietrancosta¹, Anna A. Hovhannisyan², Rodolphe Alves de Sousa¹, Nassima Bekkadour¹, Laura Ermellino^{1,3}, Enzo Tramontano³, Stéphanie Arnould⁴, Claude Sardet⁴, Julien Dairou⁵, Olivier Diaz⁶, Vincent Lotteau⁶, Sébastien Nisole⁷, Gagik Melikyan^{2*}, Jean-Philippe Herbeuval¹, Pierre-Olivier Vidalain^{1*}

¹ Chimie et Biologie, Modélisation et Immunologie pour la Thérapie (CBMIT), Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Université Paris Descartes, CNRS UMR 8601, Paris, France.

² Department of Organic Chemistry, Yerevan State University, Yerevan, Armenia.

³ Laboratory of Molecular Virology, Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy

⁴ Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France

⁵ Chimie Bio-inorganique des Dérivés Soufrés et Pharmacochimie (CBDSP), Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Université Paris Descartes, CNRS UMR 8601, Paris, France.

⁶ Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, Université Lyon 1, ENS de Lyon, Lyon, France

⁷ Institut de Recherche en Infectiologie de Montpellier CNRS UMR 9004, Université de Montpellier, Montpellier, France

*** Corresponding authors:**

Pierre-Olivier Vidalain (pierre-olivier.vidalain@inserm.fr)

Current address : Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, Université Lyon 1, ENS de Lyon, 21 Avenue Tony Garnier - 69365 Lyon Cedex 07, France

Gagik Melikyan (gagik.melikyan@yahoo.com)

Keywords: Interferon, pyrimidine biosynthesis, cerpegin, DHODH, DNA damage response

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16

- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16

1 INTRODUCTION

2 DNA and RNA syntheses require large amounts of purine and pyrimidine nucleosides
3 as precursors. This makes quickly dividing cells highly dependent on *de novo* nucleoside
4 biosynthesis, whereas quiescent and slowly growing cells essentially rely on intracellular
5 recycling of nucleosides or their uptake from extracellular fluids. Consequently, cancer cells
6 are particularly sensitive to nucleoside biosynthesis inhibitors such as 5-fluorouracil,
7 methotrexate, or 6-mercaptopurine, which are extensively used in clinical practice. Among
8 antimetabolites that are currently investigated for their antitumoral properties, molecules
9 targeting dihydroorotate dehydrogenase (DHODH), the fourth enzyme of *de novo* pyrimidine
10 biosynthesis, are the subject of intense research [1-3]. In this metabolic pathway, three
11 enzymatic steps are required to convert glutamine, aspartate, and bicarbonate into
12 dihydroorotate (DHO), which is the substrate for DHODH [3]. Its oxidation by DHODH leads
13 to orotate, which is converted into uridine monophosphate (UMP) that serves as a precursor for
14 cytidine and thymidine biosynthesis. This makes DHODH a rate-limiting enzyme in the
15 biosynthesis of pyrimidine nucleosides, and a potential target for antimetabolite development.

16 In the 90s, brequinar, a potent DHODH inhibitor passed pre-clinical studies, and was
17 evaluated for its antitumor properties in multiple phase-I and phase-II trials [1-3]. However,
18 severe adverse effects and a lack of efficacy in patients with different types of solid tumors
19 stopped its development. This setback also led to the disregard of DHODH inhibition as a
20 valuable strategy for anticancer therapies. Concomitantly, teriflunomide, another DHODH
21 inhibitor, and its related prodrug (leflunomide), were evaluated successfully and approved for
22 the treatment of rheumatoid arthritis and later on for multiple sclerosis despite significant side
23 effects [1-3]. This drug was shown to impair the proliferation of immune cells by inhibiting
24 pyrimidine biosynthesis. It also interferes through tyrosine kinase inhibition and Aryl
25 Hydrocarbon Receptor (AhR) activation, which altogether contribute to its immunosuppressive

properties [4]. Despite the failure of brequinar in past clinical studies, recent publications renewed interest in DHODH as a target in cancer therapy and both old and recent series of DHODH inhibitors were shown to have promising antitumor properties. This was demonstrated in various *in vivo* models when administered alone or in combination with other drugs, in particular in acute myeloid leukemia (AML), neuroblastoma, PTEN (Phosphatase and TENsin homolog) mutant triple negative breast cancer cells, and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutant pancreatic cancer cells [5-14]. Several DHODH inhibitors, including brequinar, leflunomide and new molecules such as BAY2402234 or PTC299, are currently being evaluated in clinical trials for cancer therapy [15,16]. Some pyrimidine biosynthesis inhibitors also exhibit broad-spectrum antiviral activity *in vitro* [1-3,17-19] and *in vivo* [20-22], opening new fields of application for this class of antimetabolites. In this context, the identification of novel DHODH inhibitors with original chemical and pharmacological properties has become a priority to overcome the limitations of existing molecules [23-27].

Beyond its cytostatic effects, DHODH inhibition is known to have a strong impact on gene expression, cell metabolism, and differentiation [5,12,14,15,28]. Our team is interested in the existing relationships between pyrimidine biosynthesis and the activation of innate immunity, with a specific focus on the interferon (IFN) response. IFN- α/β (or type I IFNs) are key antiviral and antitumoral cytokines that are produced by both immune and non-immune cells. They are released upon stimulation by viral PAMPs (Pathogen-Associated Molecular Patterns) such as double-stranded RNA molecules, or cellular DAMPs (Damage-Associated Molecular Patterns) including DNA breaks. Once bound to their target receptors, IFN- α/β mobilize the JAK (Janus Kinase) and STAT (Signal Transducers and Activators of Transcription) signaling cascade to induce a large panel of target genes, the ISGs (Interferon-Stimulated Genes), which encode numerous antiviral and antitumoral factors. IFNs and ISGs are therefore essential for the innate immune response against viruses and for the control of

1 carcinogenesis [29,30]. Most interestingly, it is now well documented that pyrimidine
2 biosynthesis inhibitors (i) induce some ISGs by a non-canonical and IFN-independent pathway,
3 and (ii) enhance the expression of IFNs and ISGs when induced by viruses or viral PAMPs
4 such as double-stranded RNA molecules [22,31-41]. Data from the literature suggest that
5 DHODH inhibitors amplify the cellular response to type I IFNs, but this was only shown using
6 a reporter gene containing Interferon-Stimulated Response Elements (ISRE) driving
7 transcription of luciferase and never explored in detail [32,34]. The mechanism by which the
8 inhibition of pyrimidine biosynthesis promotes the expression of IFNs and ISGs remains poorly
9 understood and thus needs to be further documented [22,32,36,40,41]. The positive interaction
10 between the inhibition of pyrimidine biosynthesis and the innate immune response likely
11 contributes to the antiviral activity of DHODH inhibitors and it is tempting to speculate that it
12 could also participate to the antitumor effect of these molecules as well.

13 DHODH, anchored by its N-terminal extremity to the internal mitochondrial membrane,
14 uses flavin mononucleotide (FMN) and ubiquinone (or coenzyme Q₁₀) as cofactors in a two-
15 step redox reaction. Ubiquinone is usually located in the mitochondrial membrane. Close
16 contact between DHODH and the membrane allows ubiquinone to shuttle into a hydrophobic
17 channel of this enzyme in order to contact FMN as recently modelled [42]. A majority of
18 DHODH inhibitors that have been described in the literature compete with ubiquinone for
19 binding to this channel, and interact with a limited number of well-characterized residues [1-
20 3]. Here, we took advantage of three high-definition structures available in the Protein Data
21 Bank (PDB) for human DHODH bound to unrelated inhibitors to develop and benchmark a
22 pipeline for *in silico* screening (4OQV, 3KVJ, 4RR4). This led to the identification of P1788,
23 a compound featuring structural components of the plant alkaloid cerpegin [43,44], as a new
24 class of pyrimidine biosynthesis inhibitors. We then used this compound to establish that
25 cellular response to both type-I and II IFNs is amplified in cell cultures where pyrimidine

1 biosynthesis is blocked. We provide evidence that pyrimidine biosynthesis inhibition by P1788
2 activates the DNA damage response to amplify the interferon response. Altogether, our results
3 reinforce the link between this metabolic pathway and the innate immune response and its
4 therapeutic potential in various acute and chronic diseases.

6 MATERIALS AND METHODS

7 Chemical syntheses

8 All solvents and chemicals were purchased from the Armenian Institute of Applied
9 Chemistry (ARIAC). Dimethylformamide (DMF), dimethylacetal (DMA) and xylene were
10 dried using standard. ^1H NMR and ^{13}C NMR spectra were recorded in deuterated dimethyl
11 sulfoxide (DMSO- d_6) at ambient temperature using a 500 MHz nuclear magnetic resonance
12 (NMR) spectrometer equipped with a 5 mm cryogenically cooled probe $^1\text{H}/^{13}\text{C}/^2\text{D}$ optimized
13 for carbon-13 detection with z-gradients. The chemical shifts were reported in ppm downfield
14 from tetramethylsilane (TMS). For compounds P2702, P2703, P2705 and P2706, ^1H NMR and
15 ^{13}C NMR spectra were recorded with a Varian Mercury 300 spectrometer operating at 300 MHz
16 and 75MHz with TMS as internal standard in DMSO- d_6 / CCl_4 solution at 303 K. Electrospray
17 ionization (ESI) and high resolution mass spectrometry (HRMS) analyses were conducted
18 using a Thermo Scientific High Resolution Exactive Orbitrap Mass spectrometer. The
19 measurements were performed on the NMR platform and Mass spectrometry platform of
20 UMR8601 CNRS laboratory. Elemental analyses were carried out by the CNRS microanalysis
21 service at Gif-sur-Yvette. Melting points were determined on a Kofler hot-stage microscope
22 and are uncorrected.

23 *1. Procedure for the Synthesis of Cerpegin N-Substituted Derivatives.*

24 The general procedure used for the synthesis of substituted cerpegin analogs was
25 described in our previous reports [43,45]. Initial (E)-ethyl 4-(2-(dimethylamino)vinyl)-5,5-
26 disubstituted-2-oxo-2,5-dihydrofuran-3-carboxylates (**II**) were synthesized according to

previously described methods [43-46]. Briefly, condensation of 2-oxo-2,5-dihydrofurans (**I**; 10 mmol) and DMF/DMA (1.44 mL; 12 mmol) was achieved in 3 h in boiling anhydrous xylene (10 mL) to give the corresponding compounds (**II**) in yields of up to 80-90% (**Scheme 1**). In a flask fitted with a reflux, compound (**II**) (10 mmol) and the corresponding amine (40 mmol) were mixed in anhydrous xylene (7 mL). In the case of amines with low boiling points (bp <100°C) the reaction was undertaken without xylene using an excess of amine. The mixture was boiled for 15 h (extra 2 h after cessation of dimethylamine evolution), cooled to room temperature, and 5 mL of light petroleum was added. The resulting precipitates were filtered, washed with ether and dried. Yields and physical data of the resulting compounds are provided in Supplementary Materials and Methods.

2. Synthesis of *N*-cyclopropyl-4-methyl-2-oxo-1-oxaspiro[4.5]dec-3-ene-3-carboxamide (P2708).

A mixture of ethyl 4-methyl-2-oxo-1-oxaspiro[4.5]dec-3-ene-3-carboxylate (2.38 g; 10 mmol) and cyclopropylamine (0.9 mL; 13 mmol) in ethanol (1 mL) was left at room temperature 20 h. The resulting precipitate was filtered, washed with cold ether and recrystallized from ethanol. Yields and physical data of the resulting compound are provided in Supplementary Materials and Methods.

In silico screening

The *in silico* docking was performed with Discovery Studio (Discovery Studio Modeling Environment, release 4.5; Dassault Systemes BIOVIA: San Diego, 2015) as an interface to LibDock, a docking algorithm developed by Diller and Merz [47]. LibDock uses protein site features called HotSpots which are tagged as polar or apolar. Prior to the docking procedure, the receptor HotSpot file was calculated. In parallel, ligands were prepared (*i.e.* tautomer generation, protonation depending of pKa, or stereoisomer generation), then random

ligand conformations were generated for each ligand structure by high-temperature molecular dynamics using the BEST algorithm. The different conformations of ligands were placed into the active site and HotSpots were matched as triplets. After a manual optimization and curation step, the ligand poses were scored. Because ligand hydrogens were removed during the docking process, they were added back to the ligand poses and optimized by minimization. The ligand poses with the highest LibDock scores were retained and clustered according to their binding mode.

Cells and culture conditions

Cells were cultured at 37°C and 5% CO₂ in Dulbecco's Modified Eagle's Medium (DMEM; Sigma-Aldrich; D6429) containing 10% fetal calf serum (FCS; Sigma-Aldrich; F0804), penicillin and streptomycin. Experiments were performed on HEK-293 cells stably transfected with the ISRE-Luciferase reporter gene (ISRE-Luc), with or without NanoLuc as an additional reporter gene [32,48]. ISRE-Luc and ISG expression levels were unaffected by the presence of this additional reporter gene, and data from cells with or without NanoLuc were treated indifferently. Human peripheral blood mononuclear cells (PBMC) from one healthy donor were isolated by density centrifugation with Lymphoprep medium (StemCell Technologies) from leucocytes concentrates obtained when plateletpheresis was performed (Etablissement Français du Sang; Paris; France). To activate PBMCs, cells were treated for 24 h with the TLR7/8 ligand R848 at 5 µg/ml (Sigma Aldrich) and supernatants were harvested. Cytokine expression levels were assessed using the LEGENDplex Human Anti-Virus Response Panel (BioLegend). Results are presented in Supplementary Table I.

Reagents, cytokines and small compounds

1 Firefly luciferase expression in culture wells was measured using the Bright-Glo
2 (Promega) or Britelite plus reagents (PerkinElmer), according to the manufacturer's
3 recommendations. Cellular viability was determined by quantification of adenosine
4 triphosphate (ATP) in culture wells using the CellTiter-Glo assay (Promega). Bioluminescence
5 was measured for 0.1 s with a luminometer (EnSpire; PerkinElmer). Recombinant IFN- α was
6 from Sigma-Aldrich or PBL Assay Science. Recombinant IFN- γ was from Roussel Uclaf (a
7 kind gift of Dr. Mounira Chelbi-Alix) or Miltenyi Biotech. Uridine, orotate, dihydroorotate,
8 PF477736 (Checkpoint Kinase 1 inhibitor), mirin (MRE11 inhibitor), C646 (P300/CREB-
9 Binding Protein inhibitor), teriflunomide, brequinar, and mitoxantrone were all from Sigma
10 Aldrich. Vidofludimus was from Selleckchem. AZD6738 (Ataxia telangiectasia and Rad3-
11 related kinase inhibitor) was from Euromedex.

13 ***Metabolite analysis***

14 Nucleoside/nucleotide quantification in HEK-293 cells was performed by high-
15 performance liquid chromatography (HPLC)-coupled spectrophotometry as previously
16 described in [38]. Experimental details are provided in the "Supplementary Materials and
17 Methods".

19 ***Gene expression analysis by RT-qPCR.***

20 ISG expression levels were determined by Reverse Transcription and quantitative
21 Polymerase Chain Reaction (RT-qPCR) as follows. Total RNAs were extracted from 2×10^5
22 cells using the RNeasy Micro kit including DNase (Qiagen). Reverse transcription of cellular
23 RNA into cDNA was achieved using the RevertAid H Minus first-strand cDNA synthesis kit
24 (Thermo Scientific). Real-time PCRs were performed in duplicate using the Takyon ROX
25 SYBR MasterMix dTTP blue kit (Eurogentec) and a 7900HT Fast RT-PCR system (Applied

Biosystems). Transcripts were quantified using the following program: 3 min at 95°C, followed by 35 cycles of 15 s at 95°C, 25 s at 60°C, and 25 s at 72°C. For each transcript, CT values were normalized both to the expression levels of RPL13A (60S ribosomal protein L13a) and unstimulated control samples using the $2^{-\Delta\Delta CT}$ method. The primers used for the quantification of transcripts are presented in Supplementary Table II.

γH2AX immunostaining

Cells were harvested after 24 h of culture, washed with PBS, trypsinized and fixed for 30 min in paraformaldehyde (PFA 4%). Cells were washed and permeabilized with Perm Buffer III (BD Biosciences) for 5 min. After one washing step, cells were stained with a mouse monoclonal anti-γH2AX antibody (1/400 dilution, 3F2 Clone, ThermoFisher) or a matching isotypic control in phosphate-buffered saline (PBS) + 2% bovine serum albumin (BSA). After 45 min at 4°C, cells were washed again and incubated with a secondary Alexa Fluor 488-conjugated goat anti-mouse antibody (1/500, A21121, ThermoFisher). Cells were washed after 45 min at 4°C of incubation, and analyzed by flow cytometry using a FACSCanto II (BD Biosciences).

RESULTS

In silico identification of DHODH inhibitors.

Ubiquinone is a rather large cofactor made of a 1,4-benzoquinone and a tail of 10 isoprenyl chemical subunits (Fig. 1A). The structure of human DHODH bound to ubiquinone, or its reduced form ubiquinol, has not been resolved yet. However, more than 50 co-structures of human DHODH featuring chemical inhibitors are available in the PDB. The vast majority of these inhibitors were found to bind a hydrophobic funnel localized at the contact interface of DHODH with the mitochondrial membrane. This lipophilic pocket was considered as the

1 binding site for ubiquinone allowing a direct contact with FMN at its extremity as recently
2 modeled by Costeira-Paulo J. et al [42]. As shown in Fig. 1A, our molecular docking protocol
3 confirmed that ubiquinone perfectly fits within this binding pocket. We also validated that
4 Arg136, which is essential for DHODH activity and mutated in patients with Miller syndrome,
5 interacts with one of the keto groups of ubiquinone as reported in [42]. To perform the
6 molecular docking-based screening, we selected in PDB three available high-resolution
7 structures of DHODH binding chemically-unrelated inhibitors: 4OQV, 3KVJ and 4RR4
8 [49,50]. These structures were not selected on the basis of the activity of the compounds, but
9 because the compounds display different binding modes to human DHODH. Indeed, all three
10 compounds are interacting with Arg136 and FMN in the hydrophobic funnel but the rest of the
11 interactions with DHODH are highly diverse (Fig. 1B). This provided three slightly different
12 DHODH structures to undertake an *in silico* screening. To benchmark our screening protocol,
13 we showed that algorithm-based docking of each inhibitor perfectly matched the corresponding
14 X-ray derived DHODH structure as assessed by a low Root-Mean-Square Deviation (RMSD)
15 comparison (Fig. 1B).

16 The virtual high-throughput screening (vHTS) was performed on a set of 1,587
17 compounds from Yerevan State University, a chemical library that encompasses a large
18 diversity of original structures. To ensure a time/precision ratio compatible with vHTS, we used
19 a protocol in which amino acid side chains of the protein are left flexible only around the
20 binding site, and we tested 10 random conformers for each ligand. The resulting ligand poses
21 were further filtered to select compounds expected to bind Arg136 and FMN, and then ranked
22 according to their docking scores as described in the Material and Methods section. The entire
23 library was screened against the three selected DHODH structures. Finally, a total of 26, 49,
24 and 55 compounds respectively fulfilled our criteria when using the 4OQV, 3KVJ and 4RR4
25 structures (Fig. 1C). To further increase the stringency of our screening, we selected the 11

compounds identified with at least two of the three abovementioned structures. Interestingly, this subset included two molecules, P2703 and P1788 (Fig. 1D), which featured a 1,1,5-trimethylfuro[3,4-*c*]pyridine-3,4(1*H*,5*H*)-dione component similar to one seen in the alkaloid cerpegin. To our knowledge, such double-ringed structure with two adjacent keto groups contacting Arg136 was new for DHODH inhibitors and thus deserved further investigations.

Functional validation of selected hits.

Since our main interest in DHODH inhibitors is their capacity to boost the cellular innate immune response, we used a reporter cell line expressing luciferase under the control of five interferon-stimulated response elements (ISRE-Luc) to assess the biological activity of the selected compounds. We and other groups have previously shown that in such a reporter system, cellular response to IFN- α/β is amplified by DHODH inhibitors [32,34]. Cells were incubated with increasing concentrations of selected compounds in the presence of recombinant IFN- α , and luciferase activity was quantified 24 h later. Of the 11 compounds tested, 9 were inactive but the two related compounds P2703 and P1788 efficiently increased cellular response to IFN- α (Fig. 2A). To further confirm the inhibition properties of this chemical series, we tested the capacity of P1788 to block cellular proliferation, a phenotype that is also associated with DHODH inhibition. P1788 efficiently inhibited the proliferation of HEK-293 cells when monitored over three days (Fig. 2B).

Structure activity relationships

To determine some structure activity relationship for this chemical series, and confront them with the docking model determined for P2703 and P1788 (Fig. 1D), we prepared the array of chemical analogs of cerpegin depicted in Fig. 3. Each compound was tested for its ability to boost cellular response to IFN- α using ISRE-Luc reporter cells as shown in Fig. 2A. A dose-

response ranging from 0.8 to 150 μ M was obtained for each molecule, and the corresponding pEC50s were calculated to compare their biological effect (Fig. 3). Norcerpegin (1,1-dimethylfuro[3,4-*c*]pyridine-3,4(1*H*,5*H*)-dione), the original scaffold of this chemical series, was inactive. The difference of effect seen between P1788 and compounds P2512, P1781 or P2705 demonstrated that a cyclopropyl substituent on the nitrogen was essential. Furthermore, compounds with the larger N-cyclobutyl (P2707), N-cyclopentyl (P1792), or N-cyclohexyl (P1793) groups were also inactive. Similarly, P2706 exhibiting an extended cyclopropylmethyl group showed no activity at tested concentrations. Altogether, these results support our docking model in which this cyclopropyl group fully occupies the DHODH hydrophobic pocket made of FMN, Val134 and Val143 (Fig. 1D). We also found that a double hydrophobic substitution on position 1 of the furopyridine scaffold was essential as seen for compounds featuring a spirocyclopentane (P2717), a spirocyclohexane (P1788) or a phenyl and a methyl group (P2703). This is consistent with our docking model where such substituents interact with Ala59 or Ala55 at the entry side of the hydrophobic pocket (Fig. 1D). Finally, opening the pyridine group as in P2708 also impaired the biological activity of the molecule. This last result is in line with a structuring role for the furopyridine scaffold. Altogether, these results validate our docking model for P2703 and P1788 in the ubiquinone binding pocket of DHODH.

To compare the activity of P2703 and P1788 with well-characterized inhibitors of DHODH, teriflunomide, vidofludimus and brequinar were evaluated in the same cellular assay (Fig. 3). Teriflunomide and vidofludimus were significantly more active than P2703 and P1788 (EC50 = 8.9 and 2.8 μ M vs 27 and 44 μ M, respectively), but all four molecules showed EC50s within the micromolar range. Only brequinar was much more active with an EC50 equal to 56 nM. Because P2703 and P1788 were within a range of activity close to fully optimized molecules like teriflunomide or vidofludimus, we decided to further investigate the properties of these molecules. Although P2703 was slightly more active, P1788 was selected as the

1 prototype of this chemical series because a larger batch had been produced and was readily
2 available.

4 ***P1788 targets the pyrimidine biosynthesis pathway***

5 To demonstrate that P1788 is indeed targeting the pyrimidine metabolism, we treated
6 cells with this molecule and quantified nucleoside levels by liquid chromatography coupled
7 with spectrophotometry. As shown in Fig. 4A, pyrimidine levels collapsed in P1788-treated
8 cells (U and C), whereas purine levels were unaffected (G and A). This shows that P1788
9 interferes with pyrimidine homeostasis as expected. We then determined if the amplification of
10 IFN- α/β signaling by P1788 is a consequence of pyrimidine depletion in treated cells. To
11 address this question, cells with the ISRE-Luc reporter gene were treated with recombinant
12 IFN- α and P1788 in the absence or presence of uridine. The addition of uridine completely
13 reverted the effect of P1788, thus demonstrating that pyrimidine depletion is indeed responsible
14 for the amplified response to IFN- α as shown in Fig. 4B. In order to determine more precisely
15 which step of pyrimidine biosynthesis is inhibited by P1788, the same experiment was
16 performed using a culture medium supplemented with either DHO or orotate (Fig. 4C). While
17 DHO showed no effect on cellular response to IFN- α , orotate completely reverted the effect of
18 P1788. As DHO and orotate are respectively the substrate and product of DHODH, these results
19 confirmed that P1788 is inhibiting this critical step of the pyrimidine biosynthesis pathway.

21 ***P1788 amplifies cellular response to both type I and type II IFNs***

22 As stated above, it has previously been shown that DHODH inhibition amplifies cellular
23 response to IFN- α/β [32,34]. However, this was only documented using an ISRE-Luc reported
24 gene and never validated by the actual monitoring of cellular ISGs. We took advantage of
25 P1788 as a novel inhibitor to address this question. Cells were treated with increasing

1 concentrations of IFN- α in the absence or presence of P1788, and expression levels of 12 ISGs
2 were determined by RT-qPCR. ISGs were induced by IFN- α alone, but P1788 further enhanced
3 their expression (Fig. 5A). For example, a 4 to 5-fold increase in Mx2 expression level was
4 observed when cells stimulated with IFN- α were co-treated with P1788 (Fig. 5B). Altogether,
5 this confirmed that P1788 can boost the cellular response to IFN- α

6 To our knowledge, it is still unknown if pyrimidine biosynthesis inhibitors are also able
7 to amplify the cellular response to IFN- γ . This is particularly interesting because this cytokine,
8 which is massively produced by Natural Killer (NK) cells and CD8⁺ T lymphocytes, plays a
9 key role in antitumoral immune responses and adaptive immunity in general. We thus
10 investigated the effects of P1788 on this pathway. Cells with the ISRE-Luc reporter gene were
11 stimulated with recombinant IFN- γ in the absence or presence of P1788. As shown in Fig. 6A,
12 the reporter gene was induced by IFN- γ , and P1788 further increased its expression. To further
13 validate this observation, we collected supernatants of human PBMCs stimulated with R848, a
14 synthetic ligand for TLR7. Such conditioned supernatants contain IFN- γ as shown in
15 Supplementary Table I and were used to stimulate cells with the ISRE-Luc reporter gene. P1788
16 strongly increased the cellular response to conditioned supernatants from PBMCs (Fig. 6B).
17 Our results demonstrate that P1788 is able to amplify cellular response to both type I and type
18 II interferons.

20 ***Key factors of the DNA damage response link P1788 to the IFN signaling pathway***

21 Pyrimidine depletion by DHODH inhibitors has been shown to block DNA replication,
22 leading to S phase accumulation and the activation of DNA damage response [9] (Fig. 7A). It
23 is also well known that DNA damage are able to prime or induce the IFN response to prevent
24 infections or tumor formation, depending on the cellular system [29,51]. The DNA damage
25 response could therefore functionally link the inhibition of DHODH to the innate immunity as

1 recently documented by Luthra P. et al [40]. To address this question in our cellular system, we
2 first determined if P1788 treatment induced the DNA damage response by measuring γ H2AX,
3 the phosphorylated form of H2AX (H2A histone family member X) on serine 139. As shown
4 in Fig. 7B, P1788 induced a significant increase in γ H2AX staining as determined by flow
5 cytometry. Similar γ H2AX levels were achieved with the reference DHODH inhibitor
6 teriflunomide but the signal was much higher with mitoxantrone, a potent topoisomerase II
7 inhibitor that induces massive DNA damage. Furthermore, P1788 effect was neutralized by the
8 addition of uridine, thus implicating pyrimidine depletion in this effect. The inhibition of *de*
9 *nov*o pyrimidine biosynthesis by P1788 is therefore associated to the induction of a mild DNA
10 damage response which probably reflects the accumulation of stalled DNA forks in S phase.

11 The exonuclease activity of the double-strand break repair protein MRE11, which is
12 part of the MRE11/RAD50/NBS1 (MRN) complex, plays an important role in the stabilization,
13 resection, and restart of stalled DNA forks (Fig. 7A). MRE11 also exhibits some endonuclease
14 activity involved in the cleavage and release of single-stranded DNA from the resection site
15 which contributes to IFN activation [52]. We tested the effect of mirin, an inhibitor of the
16 MRE11 nuclease activity, on the cellular response to IFN- α in the absence or presence of
17 P1788. As shown in Fig. 7C, mirin completely abolished the booster effect of P1788 on ISRE-
18 Luc induction by IFN- α . Cellular viability was not affected by this treatment as shown in Supp.
19 Fig. 1A. The Ataxia telangiectasia and Rad3-related kinase (ATR) are co-activated with the
20 MRN complex by single-stranded DNA breaks and then phosphorylate CHK1 (Checkpoint
21 Kinase 1) to block cell cycle progression upon DNA damage [53]. We tested potent inhibitors
22 of either ATR (AZD6738) or CHK1 (PF477736) in our system. ATR or CHK1 inhibitors
23 abolished the effects of P1788 on the IFN- α response, further supporting a role of the DNA
24 damage response as shown in Fig. 7D and E. Interestingly, ATR or CHK1 inhibition also
25 showed significant effects on the cellular response to IFN- α in the absence of P1788. This

suggests that a steady-state activation of ATR and CHK1 in these cells somehow contributes to the IFN response. As stated, these treatments showed limited (AZD6738) or no effect (PF477736) on cellular viability (Supp. Fig. 1B). Finally, we evaluated the contribution of P300 and CBP (CREB-Binding protein), two related histone acetyltransferases that are activated downstream of the DNA damage response but also regulate the expression of ISGs. We thus treated cells with C636, a small compound inhibiting both P300 and CBP, and induced the ISRE-Luc reporter gene with IFN- α with or without P1788. As shown in Fig. 7F, the inhibition of P300/CBP slightly decreased cellular response to IFN- α , but most importantly abolished the effect of P1788. These results confirm the functional link between the DNA damage response and the IFN-potentiating effect of P1788.

DISCUSSION

De novo pyrimidine biosynthesis is essential to fulfill the metabolic needs of quickly proliferating cells. As such, there is an increased interest in the field of cancer for molecules blocking critical steps of this enzymatic pathway. Here, we detailed the identification of P1788 and related molecules as a new series of pyrimidine biosynthesis inhibitors. These compounds were selected by virtual screening using three structures of DHODH co-crystallized with chemically distinct inhibitors bound to the ubiquinone/ubiquinol pocket. This approach was previously used by other teams and our results confirm its efficacy [54,57]. We then established the inhibition of pyrimidine biosynthesis pathway in P1788-treated cells by measuring nucleoside levels and using cellular response to IFN- α as a functional readout. The fact that orotate but not DHO nullified the effects of P1788 in this test supports the inhibition of DHODH by this molecule. It is of interest that P1788 and related molecules of this chemical series feature the unique chemical scaffold found in the alkaloid cerpegin (Fig. 3)[43,44]. Cerpegin is found in the Indian plant *Ceropegia juncea*, which has been used for centuries in folk medicine as a

1 tranquilizer, anti-inflammatory, analgesic, and anti-ulcer therapy. Modern studies showed that
2 compounds with the cerpegin scaffold inhibit the 20S subunit of the proteasome [43,45]. The
3 results described here show that compounds also based on the cerpegin scaffold but with
4 different additional chemical groups inhibit pyrimidine biosynthesis. The two-edged fused
5 polycyclic moieties of this chemical series are actually reminiscent of known DHODH
6 inhibitors, including brequinar, dicoumarol, and DD778 that we recently described [38].
7 Brequinar interacts with Arg136 of DHODH through its carboxylic acid group whereas in
8 dicoumarol, the lactone oxygen atom was suggested to play this role [58]. According to our *in*
9 *silico* model, the interaction of P1788 with Arg136 is mediated by the diketone motif. To our
10 knowledge, this mode of interaction was not previously reported for DHODH inhibitors and
11 clearly distinguishes the P1788 series from known DHODH inhibitors.

12 We took advantage of our lead molecule P1788 to characterize in details the impact of
13 pyrimidine biosynthesis inhibition on cellular response to IFNs. It is well known that DHODH
14 inhibition can (i) induce ISGs independently of IFN production or JAK/STAT signaling and
15 (ii) amplify the expression of both ISGs and IFN genes in response to double-stranded RNA
16 molecules, a viral PAMP that binds and activates RIG-like receptors (RLRs). Literature also
17 suggested that cellular response to type I IFNs is amplified when DHODH is inhibited as
18 assessed with an ISRE-Luc reporter gene [32,34]. Here, we have analyzed a dozen of ISGs by
19 RT-qPCR, and found that their induction by recombinant IFN- α is, as expected, enhanced in
20 the presence of P1788. This illustrates that the cellular stress associated to pyrimidine
21 deprivation is acting at multiple steps of the innate immune response. Most interestingly, we
22 also found that P1788 amplifies cellular response to IFN- γ . This was shown using purified
23 recombinant IFN- γ or conditioned supernatants from activated PBMCs. IFN- γ activates a
24 signaling cascade that significantly differs from IFN- α/β as it binds a specific receptor
25 (IFNGR1/2) and mobilizes Jak1/Jak2 kinases — as opposed to Jak1/Tyk2 for IFN- α/β — to

1 phosphorylate STAT1. STAT2 is not involved in the signaling cascade induced by IFN- γ . Our
2 results and the literature suggest that a common mechanism triggered by pyrimidine deprivation
3 amplifies cellular response to both IFN- α/β , IFN- γ , and RLR ligands. IFNs rely on STAT1/2
4 for gene transcription, whereas RLRs activate Interferon Regulatory Factors 3 (IRF3). It is
5 therefore tempting to speculate that a common costimulatory factor associates to these
6 transcription factors when pyrimidine biosynthesis is impaired. Discovering this mechanism
7 remains a major challenge in our understanding of the mechanisms linking pyrimidine
8 metabolism to innate immunity.

9 Here, we showed that P1788 treatment was associated to the induction of a DNA
10 damage response as assessed by γ H2AX staining. Furthermore, the enhanced response to IFN-
11 α was dependent on MRE11, ATR, CHK1, and P300/CBP. MRE11, ATR, and CHK1 are all
12 activated by single-stranded genomic DNA, in particular at stalled DNA replication forks which
13 likely accumulate when intracellular pyrimidine concentration drops below a certain threshold
14 [52]. This further supports the idea that the DNA damage response represents the functional
15 link between the inhibition of pyrimidine biosynthesis and the innate immune response. Most
16 interestingly, we and others have previously shown that Interferon Regulatory Factor 1 (IRF1)
17 is essential to ISG induction in cells treated with pyrimidine biosynthesis inhibitors alone,
18 double-stranded RNA, or both [32,40]. IRF1 is a transcription factor that is upregulated by the
19 DNA damage response and promotes the expression of ISGs, either alone or in association with
20 STATs and IRFs [59,60]. In addition, it was shown that IRF1-mediated transcription relies on
21 P300/CBP, two related histone acetyltransferases that we implicated in the signaling cascade
22 downstream of P1788 [61]. In a recent report by Luthra et al, it has been shown that DNA
23 damage associated with the inhibition of pyrimidine biosynthesis activate ATM (Ataxia
24 Telangiectasia Mutated), a kinase activated by double-stranded DNA breaks, which was
25 essential to the induction of ISGs by pyrimidine biosynthesis inhibitors [40]. In line with this

work, we conclude from our observations that the DNA damage response links pyrimidine deprivation to the innate immune response and to IRF1, and show that P300/CBP is also involved in this phenomenon.

In conclusion, we have identified and characterized a new series of compounds inhibiting pyrimidine biosynthesis. Future work will aim at improving these compounds to obtain more potent inhibitors with optimized pharmacological properties. These molecules enhance cellular response to IFN- α/β , and DNA damage response plays a key role in this mechanism. Most importantly, we showed that cellular response to IFN- γ is also enhanced in the presence of P1788. This latter finding is opening exciting perspectives in cancer therapy as IFN- γ contributes to the antitumoral activity of both NK cells and CD8⁺ T lymphocytes [62]. This suggests that the benefit of DHODH inhibitors relies not only on their cytostatic effects but also on their capacity to boost an antitumoral response. If confirmed *in vivo* this would represent a significant step toward the development of this new category of antitumoral drugs.

ACKNOWLEDGMENTS

We acknowledge the technical support of Stéphanie Dupuy from the Flow Cytometry Platform at Université Paris Descartes. We thank the chemical library UMR8601 of Paris Descartes University for preparing and providing access to Yerevan's complete database for virtual and physical screening. We thank Dr. Farah Hodeib and Dr. Yves Janin for proofreading the manuscript. This work was supported by the Agence Nationale de la Recherche (ChemInnate program to POV and SN), Campus France (Programme CEDRE), SantImmune from the Fondation Paris Descartes, the Centre National de la Recherche Scientifique (CNRS; www.cnrs.fr), and the Institut National de la Santé Et de la Recherche Médicale (INSERM). SH was supported by the National Council for Scientific Research (Lebanon) and the Université Saint-Esprit de Kaslik (USEK).

DECLARATION OF INTEREST

Structures and DHODH-inhibitory activities of the original compounds described in this manuscript have been patented.

REFERENCES

- [1] H. Munier-Lehmann, P.-O. Vidalain, F. Tangy, Y.L. Janin, On dihydroorotate dehydrogenases and their inhibitors and uses, *J. Med. Chem.* 56 (2013) 3148–3167. <https://doi.org/10.1021/jm301848w>.
- [2] M.L. Lolli, S. Sainas, A.C. Pippione, M. Giorgis, D. Boschi, F. Dosio, Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy, *Recent Patents Anticancer Drug Discov.* 13 (2018) 86–105. <https://doi.org/10.2174/1574892812666171108124218>.
- [3] J.T. Madak, A. Bankhead, C.R. Cuthbertson, H.D. Showalter, N. Neamati, Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer, *Pharmacol. Ther.* (2018). <https://doi.org/10.1016/j.pharmthera.2018.10.012>.
- [4] E.F. O'Donnell, K.S. Saili, D.C. Koch, P.R. Kopparapu, D. Farrer, W.H. Bisson, L.K. Mathew, S. Sengupta, N.I. Kerkvliet, R.L. Tanguay, S.K. Kolluri, The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor, *PloS One.* 5 (2010). <https://doi.org/10.1371/journal.pone.0013128>.
- [5] D.B. Sykes, Y.S. Kfoury, F.E. Mercier, M.J. Wawer, J.M. Law, M.K. Haynes, T.A. Lewis, A. Schajnovitz, E. Jain, D. Lee, H. Meyer, K.A. Pierce, N.J. Tolliday, A. Waller, S.J. Ferrara, A.L. Eheim, D. Stoeckigt, K.L. Maxcy, J.M. Cobert, J. Bachand, B.A. Szekely, S. Mukherjee, L.A. Sklar, J.D. Kotz, C.B. Clish, R.I. Sadreyev, P.A. Clemons, A. Janzer, S.L. Schreiber, D.T. Scadden, Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia, *Cell.* 167 (2016) 171–186.e15. <https://doi.org/10.1016/j.cell.2016.08.057>.
- [6] T.A. Lewis, D.B. Sykes, J.M. Law, B. Muñoz, J.K. Rustiguel, M.C. Nonato, D.T. Scadden, S.L. Schreiber, Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia, *ACS Med. Chem. Lett.* 7 (2016) 1112–1117. <https://doi.org/10.1021/acsmchemlett.6b00316>.
- [7] D. Mathur, E. Stratikopoulos, S. Ozturk, N. Steinbach, S. Pegno, S. Schoenfeld, R. Yong, V.V. Murty, J.M. Asara, L.C. Cantley, R. Parsons, PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition, *Cancer Discov.* 7 (2017) 380–390. <https://doi.org/10.1158/2159-8290.CD-16-0612>.
- [8] S. Zhu, X. Yan, Z. Xiang, H.-F. Ding, H. Cui, Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo, *PloS One.* 8 (2013) e71555. <https://doi.org/10.1371/journal.pone.0071555>.
- [9] S. Arnould, G. Rodier, G. Matar, C. Vincent, N. Pirot, Y. Delorme, C. Berthet, Y. Buscail, J.Y. Noël, S. Lachambre, M. Jarlier, F. Bernex, H. Delpech, P.O. Vidalain, Y.L. Janin, C. Theillet, C. Sardet, Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition, *Oncotarget.* 8 (2017) 95206–95222. <https://doi.org/10.18632/oncotarget.19199>.
- [10] M.J.G.W. Ladds, I.M.M. van Leeuwen, C.J. Drummond, S. Chu, A.R. Healy, G.

Popova, A. Pastor Fernández, T. Mollick, S. Darekar, S.K. Sedimbi, M. Nekulova, M.C.C. Sachweh, J. Campbell, M. Higgins, C. Tuck, M. Popa, M.M. Safont, P. Gelebart, Z. Fandalyuk, A.M. Thompson, R. Svensson, A.-L. Gustavsson, L. Johansson, K. Färnegårdh, U. Yngve, A. Saleh, M. Haraldsson, A.C.A. D'Hollander, M. Franco, Y. Zhao, M. Håkansson, B. Walse, K. Larsson, E.M. Peat, V. Pelechano, J. Lunec, B. Vojtesek, M. Carmena, W.C. Earnshaw, A.R. McCarthy, N.J. Westwood, M. Arsenian-Henriksson, D.P. Lane, R. Bhatia, E. McCormack, S. Laín, A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage, *Nat. Commun.* 9 (2018) 1107. <https://doi.org/10.1038/s41467-018-03441-3>.

[11] M. Koundinya, J. Sudhalter, A. Courjaud, B. Lionne, G. Touyer, L. Bonnet, I. Menguy, I. Schreiber, C. Perrault, S. Vougier, B. Benhamou, B. Zhang, T. He, Q. Gao, P. Gee, D. Simard, M.P. Castaldi, R. Tomlinson, S. Reiling, M. Barrague, R. Newcombe, H. Cao, Y. Wang, F. Sun, J. Murtie, M. Munson, E. Yang, D. Harper, M. Bouaboula, J. Pollard, C. Grepin, C. Garcia-Echeverria, H. Cheng, F. Adrian, C. Winter, S. Licht, I. Cornella-Taracido, R. Arrebola, A. Morris, Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers, *Cell Chem. Biol.* 25 (2018) 705-717.e11. <https://doi.org/10.1016/j.chembiol.2018.03.005>.

[12] M. Bajzikova, J. Kovarova, A.R. Coelho, S. Boukalova, S. Oh, K. Rohlenova, D. Svec, S. Hubackova, B. Endaya, K. Judasova, A. Bezawork-Geleta, K. Kluckova, L. Chatre, R. Zabalova, A. Novakova, K. Vanova, Z. Ezrova, G.J. Maghzal, S. Magalhaes Novais, M. Olsinova, L. Krobova, Y.J. An, E. Davidova, Z. Nahacka, M. Sobol, T. Cunha-Oliveira, C. Sandoval-Acuña, H. Strnad, T. Zhang, T. Huynh, T.L. Serafim, P. Hozak, V.A. Sardao, W.J.H. Koopman, M. Ricchetti, P.J. Oliveira, F. Kolar, M. Kubista, J. Truksa, K. Dvorakova-Hortova, K. Pacak, R. Gurlich, R. Stocker, Y. Zhou, M.V. Berridge, S. Park, L. Dong, J. Rohlena, J. Neuzil, Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells, *Cell Metab.* 29 (2019) 399-416.e10. <https://doi.org/10.1016/j.cmet.2018.10.014>.

[13] X. Wang, K. Yang, Q. Wu, L.J.Y. Kim, A.R. Morton, R.C. Gimple, B.C. Prager, Y. Shi, W. Zhou, S. Bhargava, Z. Zhu, L. Jiang, W. Tao, Z. Qiu, L. Zhao, G. Zhang, X. Li, S. Agnihotri, P.S. Mischel, S.C. Mack, S. Bao, J.N. Rich, Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells, *Sci. Transl. Med.* 11 (2019). <https://doi.org/10.1126/scitranslmed.aau4972>.

[14] M. Hosseini, L. Dousset, P. Michon, W. Mahfouf, E. Muzotte, V. Bergeron, D. Bortolotto, R. Rossignol, F. Moisan, A. Taieb, A.-K. Bouzier-Sore, H.R. Rezvani, UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis, *Oncogenesis.* 8 (2019) 52. <https://doi.org/10.1038/s41389-019-0161-z>.

[15] S. Christian, C. Merz, L. Evans, S. Gradl, H. Seidel, A. Friberg, A. Eheim, P. Lejeune, K. Brzezinka, K. Zimmermann, S. Ferrara, H. Meyer, R. Lesche, D. Stoeckigt, M. Bauser, A. Haegebarth, D.B. Sykes, D.T. Scadden, J.-A. Losman, A. Janzer, The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies, *Leukemia.* (2019). <https://doi.org/10.1038/s41375-019-0461-5>.

[16] L. Cao, M. Weetall, C. Trotta, K. Cintron, J. Ma, M.J. Kim, B. Furia, C. Romfo, J.D. Graci, W. Li, J. Du, J. Sheedy, J. Hedrick, N. Risher, S. Yeh, H. Qi, T. Arasu, S. Hwang, W. Lennox, R. Kong, J. Petruska, Y.-C. Moon, J. Babiak, T.W. Davis, A. Jacobson, N.G. Almstead, A. Branstrom, J.M. Colacino, S.W. Peltz, Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties, *Mol. Cancer Ther.* 18 (2019) 3–16. <https://doi.org/10.1158/1535-7163.MCT-18-0863>.

- [17] A. Bonavia, M. Franti, E. Pusateri Keaney, K. Kuhen, M. Seepersaud, B. Radetich, J. Shao, A. Honda, J. Dewhurst, K. Balabanis, J. Monroe, K. Wolff, C. Osborne, L. Lanieri, K. Hoffmaster, J. Amin, J. Markovits, M. Broome, E. Skuba, I. Cornella-Taracido, G. Joberty, T. Bouwmeester, L. Hamann, J.A. Tallarico, R. Tommasi, T. Compton, S.M. Bushell, Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV), *Proc. Natl. Acad. Sci. U. S. A.* 108 (2011) 6739–6744. <https://doi.org/10.1073/pnas.1017142108>.
- [18] Q.-Y. Wang, S. Bushell, M. Qing, H.Y. Xu, A. Bonavia, S. Nunes, J. Zhou, M.K. Poh, P. Florez de Sessions, P. Niyomrattanakit, H. Dong, K. Hoffmaster, A. Goh, S. Nilar, W. Schul, S. Jones, L. Kramer, T. Compton, P.-Y. Shi, Inhibition of dengue virus through suppression of host pyrimidine biosynthesis, *J. Virol.* 85 (2011) 6548–6556. <https://doi.org/10.1128/JVI.02510-10>.
- [19] H.-H. Hoffmann, A. Kunz, V.A. Simon, P. Palese, M.L. Shaw, Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis, *Proc. Natl. Acad. Sci. U. S. A.* 108 (2011) 5777–5782. <https://doi.org/10.1073/pnas.1101143108>.
- [20] M. Marschall, I. Niemann, K. Kosulin, A. Bootz, S. Wagner, T. Dobner, T. Herz, B. Kramer, J. Leban, D. Vitt, T. Stamminger, C. Hutterer, S. Strobl, Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis, *Antiviral Res.* 100 (2013) 640–648. <https://doi.org/10.1016/j.antiviral.2013.10.003>.
- [21] C.-F. Yang, B. Gopula, J.-J. Liang, J.-K. Li, S.-Y. Chen, Y.-L. Lee, C.S. Chen, Y.-L. Lin, Novel AR-12 derivatives, P12-23 and P12-34, inhibit flavivirus replication by blocking host de novo pyrimidine biosynthesis, *Emerg. Microbes Infect.* 7 (2018) 187. <https://doi.org/10.1038/s41426-018-0191-1>.
- [22] N.N. Cheung, K.K. Lai, J. Dai, K.H. Kok, H. Chen, K.-H. Chan, K.-Y. Yuen, R.Y.T. Kao, Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response, *J. Gen. Virol.* 98 (2017) 946–954. <https://doi.org/10.1099/jgv.0.000758>.
- [23] F. Zeng, L. Quan, G. Yang, T. Qi, L. Zhang, S. Li, H. Li, L. Zhu, X. Xu, Structural Optimization and Structure-Activity Relationship of 4-Thiazolidinone Derivatives as Novel Inhibitors of Human Dihydroorotate Dehydrogenase, *Mol. Basel Switz.* 24 (2019). <https://doi.org/10.3390/molecules24152780>.
- [24] T. Zeng, Z. Zuo, Y. Luo, Y. Zhao, Y. Yu, Q. Chen, A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode, *FEBS Open Bio.* 9 (2019) 1348–1354. <https://doi.org/10.1002/2211-5463.12658>.
- [25] V.K. Vyas, G. Qureshi, D. Oza, H. Patel, K. Parmar, P. Patel, M.D. Ghate, Synthesis of 2-,4-,6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design, *Bioorg. Med. Chem. Lett.* 29 (2019) 917–922. <https://doi.org/10.1016/j.bmcl.2019.01.038>.
- [26] S. Sainas, A.C. Pippione, E. Lupino, M. Giorgis, P. Circosta, V. Gaidano, P. Goyal, D. Bonanni, B. Rolando, A. Cignetti, A. Ducime, M. Andersson, M. Järvå, R. Friemann, M. Piccinini, C. Ramondetti, B. Buccinnà, S. Al-Karadaghi, D. Boschi, G. Saglio, M.L. Lolli, Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors, *J. Med. Chem.* 61 (2018) 6034–6055. <https://doi.org/10.1021/acs.jmedchem.8b00373>.
- [27] J.T. Madak, C.R. Cuthbertson, Y. Miyata, S. Tamura, E.M. Petrunak, J.A. Stuckey, Y. Han, M. He, D. Sun, H.D. Showalter, N. Neamati, Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase, *J. Med. Chem.* 61 (2018) 5162–5186. <https://doi.org/10.1021/acs.jmedchem.7b01862>.
- [28] M. Hosseini, L. Dousset, W. Mahfouf, M. Serrano-Sanchez, I. Redonnet-Vernhet, S.

- 1 Mesli, Z. Kasraian, E. Obre, M. Bonneu, S. Claverol, M. Vlaski, Z. Ivanovic, W. Rachidi, T.
- 2 Douki, A. Taieb, A.-K. Bouzier-Sore, R. Rossignol, H.R. Rezvani, Energy Metabolism
- 3 Rewiring Precedes UVB-Induced Primary Skin Tumor Formation, *Cell Rep.* 23 (2018) 3621–
- 4 3634. <https://doi.org/10.1016/j.celrep.2018.05.060>.
- 5 [29] T. Li, Z.J. Chen, The cGAS-cGAMP-STING pathway connects DNA damage to
- 6 inflammation, senescence, and cancer, *J. Exp. Med.* 215 (2018) 1287–1299.
- 7 <https://doi.org/10.1084/jem.20180139>.
- 8 [30] B.S. Parker, J. Rautela, P.J. Hertzog, Antitumour actions of interferons: implications for
- 9 cancer therapy, *Nat. Rev. Cancer.* 16 (2016) 131–144. <https://doi.org/10.1038/nrc.2016.14>.
- 10 [31] R. Harvey, K. Brown, Q. Zhang, M. Gartland, L. Walton, C. Talarico, W. Lawrence, D.
- 11 Selleseth, N. Coffield, J. Leary, K. Moniri, S. Singer, J. Strum, K. Gudmundsson, K. Biron,
- 12 K.R. Romines, P. Sethna, GSK983: a novel compound with broad-spectrum antiviral activity,
- 13 *Antiviral Res.* 82 (2009) 1–11. <https://doi.org/10.1016/j.antiviral.2008.12.015>.
- 14 [32] M. Lucas-Hourani, D. Dauzonne, P. Jorda, G. Cousin, A. Lupan, O. Helynck, G.
- 15 Caignard, G. Janvier, G. André-Leroux, S. Khier, N. Escriou, P. Desprès, Y. Jacob, H. Munier-
- 16 Lehmann, F. Tangy, P.-O. Vidalain, Inhibition of pyrimidine biosynthesis pathway suppresses
- 17 viral growth through innate immunity, *PLoS Pathog.* 9 (2013) e1003678.
- 18 <https://doi.org/10.1371/journal.ppat.1003678>.
- 19 [33] M. Lucas-Hourani, H. Munier-Lehmann, F. El Mazouni, N.A. Malmquist, J. Harpon,
- 20 E.P. Coutant, S. Guillou, O. Helynck, A. Noel, A. Scherf, M.A. Phillips, F. Tangy, P.-O.
- 21 Vidalain, Y.L. Janin, Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human
- 22 Dihydroorotate Dehydrogenase (DHODH), *J. Med. Chem.* 58 (2015) 5579–5598.
- 23 <https://doi.org/10.1021/acs.jmedchem.5b00606>.
- 24 [34] K.L. Yeo, Y.-L. Chen, H.Y. Xu, H. Dong, Q.-Y. Wang, F. Yokokawa, P.-Y. Shi,
- 25 Synergistic suppression of dengue virus replication using a combination of nucleoside analogs
- 26 and nucleoside synthesis inhibitors, *Antimicrob. Agents Chemother.* 59 (2015) 2086–2093.
- 27 <https://doi.org/10.1128/AAC.04779-14>.
- 28 [35] Y. Wang, W. Wang, L. Xu, X. Zhou, E. Shokrollahi, K. Felczak, L.J.W. van der Laan,
- 29 K.W. Pankiewicz, D. Sprengers, N.J.H. Raat, H.J. Metselaar, M.P. Peppelenbosch, Q. Pan,
- 30 Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining
- 31 Hepatitis E Virus Replication, *Antimicrob. Agents Chemother.* 60 (2016) 2834–2848.
- 32 <https://doi.org/10.1128/AAC.02700-15>.
- 33 [36] D.-H. Chung, J.E. Golden, R.S. Adcock, C.E. Schroeder, Y.-K. Chu, J.B. Sotsky, D.E.
- 34 Cramer, P.M. Chilton, C. Song, M. Anantpadma, R.A. Davey, A.I. Prodhon, X. Yin, X. Zhang,
- 35 Discovery of a Broad-Spectrum Antiviral Compound That Inhibits Pyrimidine Biosynthesis
- 36 and Establishes a Type 1 Interferon-Independent Antiviral State, *Antimicrob. Agents*
- 37 *Chemother.* 60 (2016) 4552–4562. <https://doi.org/10.1128/AAC.00282-16>.
- 38 [37] E. Pery, A. Sheehy, N. Miranda Nebane, V. Misra, M.K. Mankowski, L. Rasmussen, E.
- 39 Lucile White, R.G. Ptak, D. Gabuzda, Redoxal, an inhibitor of de novo pyrimidine biosynthesis,
- 40 augments APOBEC3G antiviral activity against human immunodeficiency virus type 1,
- 41 *Virology.* 484 (2015) 276–287. <https://doi.org/10.1016/j.virol.2015.06.014>.
- 42 [38] M. Lucas-Hourani, D. Dauzonne, H. Munier-Lehmann, S. Khier, S. Nisole, J. Dairou,
- 43 O. Helynck, P.V. Afonso, F. Tangy, P.-O. Vidalain, Original Chemical Series of Pyrimidine
- 44 Biosynthesis Inhibitors That Boost the Antiviral Interferon Response, *Antimicrob. Agents*
- 45 *Chemother.* 61 (2017). <https://doi.org/10.1128/AAC.00383-17>.
- 46 [39] K. Lee, D.-E. Kim, K.-S. Jang, S.-J. Kim, S. Cho, C. Kim, Gemcitabine, a broad-
- 47 spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by
- 48 the inhibition of pyrimidine biosynthesis and nucleotide depletion, *Oncotarget.* 8 (2017)
- 49 115315–115325. <https://doi.org/10.18632/oncotarget.23258>.
- 50 [40] P. Luthra, J. Naidoo, C.A. Pietzsch, S. De, S. Khadka, M. Anantpadma, C.G. Williams,

M.R. Edwards, R.A. Davey, A. Bukreyev, J.M. Ready, C.F. Basler, Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses, *Antiviral Res.* 158 (2018) 288–302. <https://doi.org/10.1016/j.antiviral.2018.08.012>.

[41] J. Zhou, D. Wang, B.H.-Y. Wong, C. Li, V.K.-M. Poon, L. Wen, X. Zhao, M.C. Chiu, X. Liu, Z. Ye, S. Yuan, K.-H. Sze, J.F.-W. Chan, H. Chu, K.K.-W. To, K.Y. Yuen, Identification and characterization of GLDC as host susceptibility gene to severe influenza, *EMBO Mol. Med.* 11 (2019). <https://doi.org/10.15252/emmm.201809528>.

[42] J. Costeira-Paulo, J. Gault, G. Popova, M.J.G.W. Ladds, I.M.M. van Leeuwen, M. Sarr, A. Olsson, D.P. Lane, S. Laín, E.G. Marklund, M. Landreh, Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase, *Cell Chem. Biol.* 25 (2018) 309–317.e4. <https://doi.org/10.1016/j.chembiol.2017.12.012>.

[43] A. Hovhannisyan, T.H. Pham, D. Bouvier, L. Qin, G. Melikyan, M. Reboud-Ravaux, M. Bouvier-Durand, C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome, *Bioorg. Med. Chem. Lett.* 23 (2013) 2696–2703. <https://doi.org/10.1016/j.bmcl.2013.02.079>.

[44] A. Hovhannisyan, T.H. Pham, D. Bouvier, A. Piroyan, L. Dufau, L. Qin, Y. Cheng, G. Melikyan, M. Reboud-Ravaux, M. Bouvier-Durand, New C(4)- and C(1)-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform, *Bioorg. Med. Chem. Lett.* 24 (2014) 1571–1580. <https://doi.org/10.1016/j.bmcl.2014.01.072>.

[45] T.H. Pham, A. Hovhannisyan, D. Bouvier, L. Tian, M. Reboud-Ravaux, G. Melikyan, M. Bouvier-Durand, A new series of N5 derivatives of the 1,1,5-trimethyl furo[3,4-c]pyridine-3,4-dione (cerpegin) selectively inhibits the post-acid activity of mammalian 20S proteasomes, *Bioorg. Med. Chem. Lett.* 22 (2012) 3822–3827. <https://doi.org/10.1016/j.bmcl.2012.03.105>.

[46] D. Villemin, N. Cheikh, L. Liao, N. Bar, J.-F. Lohier, J. Sopkova, N. Choukchou-Braham, B. Mostefa-Kara, Two versatile routes towards Cerpegin and analogues: applications of a one pot reaction to new analogues of Cerpegin, *Tetrahedron.* 68 (2012) 4906–4918. <https://doi.org/10.1016/j.tet.2012.03.057>.

[47] D.J. Diller, K.M. Merz, High throughput docking for library design and library prioritization, *Proteins.* 43 (2001) 113–124.

[48] S. Hayek, N. Bekaddour, L. Besson, R. Alves de Sousa, N. Pietrancosta, S. Viel, N. Smith, Y. Jacob, S. Nisole, R. Mandal, D.S. Wishart, T. Walzer, J.-P. Herbeuval, P.-O. Vidalain, Identification of Primary Natural Killer Cell Modulators by Chemical Library Screening with a Luciferase-Based Functional Assay, *SLAS Discov. Adv. Life Sci. R D.* 24 (2019) 25–37. <https://doi.org/10.1177/2472555218797078>.

[49] X. Deng, S. Kokkonda, F. El Mazouni, J. White, J.N. Burrows, W. Kaminsky, S.A. Charman, D. Matthews, P.K. Rathod, M.A. Phillips, Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors, *J. Med. Chem.* 57 (2014) 5381–5394. <https://doi.org/10.1021/jm500481t>.

[50] L.R. McLean, Y. Zhang, W. Degnen, J. Peppard, D. Cabel, C. Zou, J.T. Tsay, A. Subramaniam, R.J. Vaz, Y. Li, Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures, *Bioorg. Med. Chem. Lett.* 20 (2010) 1981–1984. <https://doi.org/10.1016/j.bmcl.2010.01.115>.

[51] F. Coquel, C. Neumayer, Y.-L. Lin, P. Pasero, SAMHD1 and the innate immune response to cytosolic DNA during DNA replication, *Curr. Opin. Immunol.* 56 (2018) 24–30. <https://doi.org/10.1016/j.coi.2018.09.017>.

[52] F. Coquel, M.-J. Silva, H. Técher, K. Zadorozhny, S. Sharma, J. Nieminuszczy, C. Mettling, E. Dardillac, A. Barthe, A.-L. Schmitz, A. Promonet, A. Cribier, A. Sarrazin, W. Niedzwiedz, B. Lopez, V. Costanzo, L. Krejci, A. Chabes, M. Benkirane, Y.-L. Lin, P. Pasero,

SAMHD1 acts at stalled replication forks to prevent interferon induction, *Nature*. 557 (2018) 57–61. <https://doi.org/10.1038/s41586-018-0050-1>.

[53] J. Lee, W.G. Dunphy, The Mre11-Rad50-Nbs1 (MRN) complex has a specific role in the activation of Chk1 in response to stalled replication forks, *Mol. Biol. Cell*. 24 (2013) 1343–1353. <https://doi.org/10.1091/mbc.E13-01-0025>.

[54] T. Herz, K. Wolf, J. Kraus, B. Kramer, 4SCan/vADME: intelligent library screening as a shortcut from hits to lead compounds, *Expert Opin. Drug Metab. Toxicol.* 2 (2006) 471–484. <https://doi.org/10.1517/17425255.2.3.471>.

[55] Y. Diao, W. Lu, H. Jin, J. Zhu, L. Han, M. Xu, R. Gao, X. Shen, Z. Zhao, X. Liu, Y. Xu, J. Huang, H. Li, Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening, *J. Med. Chem.* 55 (2012) 8341–8349. <https://doi.org/10.1021/jm300630p>.

[56] V.K. Vyas, M. Ghate, Development of docking-based 3D QSAR models for the design of substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors, *SAR QSAR Environ. Res.* 24 (2013) 625–645. <https://doi.org/10.1080/1062936X.2013.792871>.

[57] M. Sucharita, B. Poorani, P. Swaminathan, An insilico workflow that yields experimentally comparable inhibitors for human DiHydroOrotate DeHydrogenase, *Curr. Comput. Aided Drug Des.* (2019). <https://doi.org/10.2174/1573409915666190528114703>.

[58] I. Fritzson, B. Svensson, S. Al-Karadaghi, B. Walse, U. Wellmar, U.J. Nilsson, D. da Graça Thrige, S. Jönsson, Inhibition of human DHODH by 4-hydroxycoumarins, fenamic acids, and N-(alkylcarbonyl)anthranilic acids identified by structure-guided fragment selection, *ChemMedChem*. 5 (2010) 608–617. <https://doi.org/10.1002/cmdc.200900454>.

[59] M. Frontini, M. Vijayakumar, A. Garvin, N. Clarke, A ChIP-chip approach reveals a novel role for transcription factor IRF1 in the DNA damage response, *Nucleic Acids Res.* 37 (2009) 1073–1085. <https://doi.org/10.1093/nar/gkn1051>.

[60] M. Abou El Hassan, K. Huang, Z. Xu, T. Yu, R. Bremner, Frequent interferon regulatory factor 1 (IRF1) binding at remote elements without histone modification, *J. Biol. Chem.* 293 (2018) 10353–10362. <https://doi.org/10.1074/jbc.RA118.002889>.

[61] D. Dornan, M. Eckert, M. Wallace, H. Shimizu, E. Ramsay, T.R. Hupp, K.L. Ball, Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53, *Mol. Cell. Biol.* 24 (2004) 10083–10098. <https://doi.org/10.1128/MCB.24.22.10083-10098.2004>.

[62] M.R. Zaidi, G. Merlino, The two faces of interferon- γ in cancer, *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 17 (2011) 6118–6124. <https://doi.org/10.1158/1078-0432.CCR-11-0482>.

Figure Legends

Figure 1. *In silico* screening procedure for the identification of novel DHODH inhibitors.

(A) DHODH structure was retrieved from PDB (3KVJ), showing orotate (red), FMN (green), and Arg136 (blue). The DHODH inhibitor present in the ubiquinone-binding site of the structure was removed and replaced by a ubiquinone analog without the hydrophobic tail to facilitate the *in silico* docking (yellow). Ubiquinone structure is shown in the upper left panel as a reference. (B) Schematic 2-D diagrams of small molecule inhibitors as bound to DHODH in PDB structures 4OQV, 3KVJ and 4RR4. For each inhibitor, the RMSD value estimates the position overlap between structural data and results of the *in silico* docking. (C) Venn diagram showing the results of the screenings performed on DHODH structures from 4OQV, 3KVJ, and 4RR4. We selected the 11 hit compounds identified in more than one screen for further evaluation. (D-E) Schematic 2-D diagrams of P2703 and P1788 bound to DHODH as determined by *in silico* docking.

Figure 2. Cellular response to IFN- α is amplified by P1788 and P2703. (A) HEK-293 cells with the ISRE-Luc reporter gene were treated with P1788, P2703 or DMSO alone in the absence or presence of IFN- α (150 IU/ml). Expression of the ISRE-Luc reporter gene was determined 24 h later, and results were normalized using cells treated with IFN- α alone as reference. (B) Cells were treated with DMSO or P1788 at different concentrations, and the number of viable cells was determined using the CellTiter-Glo reagent after 24, 48 and 72 h of culture. Results were expressed as a percentage relative to untreated cells at $t = 0$ h. Data represent means $\pm$ SD of three (A) or two (B) independent experiments. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ as calculated by one-way analysis of variance (ANOVA) with Bonferroni's post hoc test.

Figure 3. Structure/activity relationships. Chemical analogs of P1788 and P2703 were tested for their ability to boost cellular response to IFN- α in HEK-293 cells with the ISRE-Luc reporter gene. Teriflunomide, vidofludimus and brequinar were tested as reference DHODH inhibitors in the same cellular assay. pEC50s, corresponding to $-\log_{10}$ of the half maximal effective molar concentrations, were computed from a four-parameter fitting curve using Prism software (GraphPad). Binding energies were also computed by *in silico* docking for comparison with pEC50s. FTD ("failed to determine") is indicated when binding energies could not be computed. The chemical structure of cerpegin is shown as a reference.

Figure 4. P1788 is inhibiting pyrimidine biosynthesis. (A) Cells were treated with DMSO or increasing concentrations of P1788. 24 h later, cells were harvested and intracellular levels of purine (G/A) and pyrimidine (C/U) were determined by HPLC-coupled spectrophotometry. Results were normalized using DMSO-treated cells as a reference. (B) Cells were treated with increasing concentrations of IFN- α with DMSO, P1788 (80 μ M) or P1788 (80 μ M) and uridine (125 μ M). 24 h later, expression of the ISRE-Luc reporter gene was determined. Results were normalized using cells treated with DMSO + IFN- α at 250 IU/ml as a reference. (C) Same experiment as in (A), but culture medium was supplemented with 3 mM of orotate or DHO instead of uridine. Data represent means $\pm$ SD of three independent experiments. *** p <0.001 as calculated by two-way ANOVA.

Figure 5. ISG induction by IFN- α is enhanced in the presence of P1788. (A) HEK cells with the ISRE-Luc reporter gene were cultured with increasing concentrations of IFN- α and co-treated with DMSO or P1788 (80 μ M). 16 h later, induction levels of indicated ISGs were determined by RT-qPCR, and expressed as fold changes relative to control cells (DMSO alone). Results highlighted in bold correspond to statistically significant values when comparing untreated to P1788-treated cells from three independent experiments (p <0.05 determined by two-way ANOVA with Bonferroni's post hoc test). (B) Corresponding data for Mx2 mRNA expression were displayed as a bar chart showing mean values $\pm$ SD.

Figure 6. Cellular response to IFN- γ is amplified by P1788. (A) HEK-293 cells with the ISRE-Luc reporter gene were treated with DMSO or P1788 (80 μ M) in the absence or presence of recombinant IFN- γ (150 IU/ml). Luciferase activity in culture wells was determined 24 h later. Results were normalized using cells treated with DMSO + IFN- γ as reference. ** p <0.01 as calculated by two-tailed t-test. (B) Same experiment as in (A), but cells were stimulated with different dilutions ranging from 1/8 to 1/64 of conditioned supernatants from activated PBMCs. Results were normalized using cells treated with 1/8 diluted supernatants as reference. Data represent means $\pm$ SD of three independent experiments. * p <0.05; *** p <0.001 determined by two-way ANOVA with Bonferroni's post hoc test.

Figure 7. Immunostimulatory properties of P1788 is linked to DNA damage response. (A) Simplified model of the DNA damage response induced by pyrimidine deprivation at

stalled DNA replication forks. (B) Cells were treated with DMSO, P1788 (80 μ M), P1788 + uridine (Uri.; 125 μ M), teriflunomide (Ter.; 50 μ M) or mitoxantrone (Mit.; 50 nM). 24 h later, cells were harvested and γ H2AX level was determined by immunostaining and flow cytometry analysis. Data represent means $\pm$ SD of three independent experiments. ** p <0.01; *** p <0.001 as calculated by two-tailed t-test. **(C-F)** HEK-293 cells with the ISRE-Luc reporter gene were treated with DMSO, IFN- α (150 IU/ml) or IFN- α + P1788 (80 μ M), in the absence or presence of mirin (C), AZD6738 (D), PF477736 (E) or C636 (F) to inhibit MRE11, ATR, CHK1 and P300/CBP, respectively. Luciferase activity in culture wells was determined 24 h later, and results were normalized using cells treated with IFN- α alone as reference. Data represent means $\pm$ SD of at least three independent experiments (B-F). * p <0.05; ** p <0.01; *** p <0.001 as calculated by standard Student's t-test (B) or one-way ANOVA with Bonferroni's post hoc test (C-F).

Supplementary Figure 1. Cell counts in cultures treated with mirin, AZD6738, PF477736 or C636. The number of viable cells was determined in culture conditions from Fig. 7C, D, E and D using the CellTiter-Glo reagent. Results were expressed as a percentage relative to cells treated with IFN- α alone. Data represent means $\pm$ SD of three (A/C/D) or two independent (B) experiments.

Scheme 1. Synthesis of cerpegin derivatives.

R ₁ , R ₂ , R ₃	Norcerpegin	P2701	P2702	P2718	P2717	P1788	P2703	P2512	P1781	P2705	P2707	P1792	P1793	P2706	P2708
H	R ₃							R ₃							
Me	R ₁ , R ₂	R ₁ , R ₂	R ₁				R ₁		R ₃						
ethyl			R ₂	R ₁ , R ₂						R ₃					
isopropyl															
cyclopropyl		R ₃	R ₃	R ₃	R ₃	R ₃	R ₃								R ₃
cyclobutyl											R ₃				
cyclopentyl					R ₁ , R ₂							R ₃			
cyclohexyl						R ₁ , R ₂		R ₁ , R ₂	R ₁ , R ₂	R ₁ , R ₂	R ₁ , R ₂	R ₁ , R ₂	R ₁ , R ₂ , R ₃	R ₁ , R ₂	R ₁ , R ₂
cyclopropylmethyl														R ₃	
benzyl							R ₂								

Figure 1

Figure 2

A

B

Figure 3

Cerpergin

Norcerpergin

$pEC_{50} < 3.8$

FTD

P2703

$pEC_{50} = 4.57$

$E = -41.9 \text{ kcal/mol}$

P1788

$pEC_{50} = 4.35$

$E = -41.2 \text{ kcal/mol}$

P2512

$pEC_{50} < 3.8$

FTD

P1781

$pEC_{50} < 3.8$

FTD

P2705

$pEC_{50} < 3.8$

$E = -42.7 \text{ kcal/mol}$

P2707

$pEC_{50} < 3.8$

$E = -42.3 \text{ kcal/mol}$

P1792

$pEC_{50} < 3.8$

FTD

P1793

$pEC_{50} < 3.8$

FTD

P2706

$pEC_{50} < 3.8$

FTD

P2708

$pEC_{50} < 3.8$

$E = -40.6 \text{ kcal/mol}$

P2701

$pEC_{50} < 3.8$

$E = -34.7 \text{ kcal/mol}$

P2702

$pEC_{50} < 3.8$

FTD

P2718

$pEC_{50} < 3.8$

$E = -40.6 \text{ kcal/mol}$

P2717

$pEC_{50} = 4.28$

$E = -41.7 \text{ kcal/mol}$

Teriflunomide

$pEC_{50} = 5.05$

$E = -61.6 \text{ kcal/mol}$

Vidofludimus

$pEC_{50} = 5.56$

$E = -62.3 \text{ kcal/mol}$

Brequinar sodium salt

$pEC_{50} = 7.26$

$E = -47.3 \text{ kcal/mol}$

Figure 4

Figure 5

A

IFN-α (IU/ml)	DMSO					P1788				
	0	30	60	125	250	0	30	60	125	250
ISG15	1	49	66	70	76	2	123	163	200	226
IFIT3	1	21	44	56	69	2	39	69	99	129
IFIT1	1	24	37	49	65	1	51	85	115	145
IFIT2	1	6	15	28	45	2	26	61	112	165
IFI6	1	4	18	25	33	2	47	64	80	91
IFI27	1	2	14	23	33	3	44	83	117	143
IFITM3	1	2	11	13	16	1	6	12	14	15
DDX58	1	2	8	11	14	2	16	23	31	38
Mx2	1	1	2	4	7	2	7	13	20	28
IFIT5	1	2	3	3	3	1	3	3	4	5
PKR	1	1	2	3	3	1	2	3	3	4
PML	1	1	2	2	3	1	3	4	5	5

B

Figure 6

Figure 7

Supplementary Figure 1

SUPPLEMENTARY MATERIALS AND METHODS

Metabolite analysis

The protocol we used for nucleoside/nucleotide quantification in HEK-293 cells was previously described in detail [25]. Briefly, cells were plated in 6-well plates at 1×10^6 cells per well and after 24 h, P1788 (80 μ M final concentration) or DMSO alone was added. 24 h later, cells were washed with PBS and cellular pellets were deproteinized by adding an equal volume of 6% perchloric acid. After 10 min of incubation on ice and clearing of the extracts by centrifugation (13,000 rpm for 10 min at 4°C), supernatants were supplemented with double-distilled water (v/v) and neutralized by the addition of 2 M Na_2CO_3 . Extracts were analyzed by HPLC onto a C18 Supelco 5- μ m (250 by 4.6 mm) column (Sigma) at 45°C using a mobile phase delivered at a flow rate of 1 ml/min. Buffer A contained 10 mM tetrabutylammonium hydroxide, 10 mM KH_2PO_4 , and 0.25% MeOH and was adjusted to pH 6.9 with 1 M HCl. Buffer B contained 5.6 mM tetrabutylammonium hydroxide, 50 mM KH_2PO_4 , and 30% MeOH and was neutralized to pH 7.0 with 1 M NaOH. The following stepwise gradient elution program was used: A to B at 60:40 at 0 min, 40:60 at 30 min, and 40:60 at 60 min. Products were monitored spectrophotometrically at 254 nm with a diode array detector (PDA) and quantified by integration of the peak absorbance area. Calibration curves were generated with reference nucleosides. Finally, raw data were normalized to the total number of viable cells present in the well in order to take into account minor differences between culture conditions.

1 **Supplementary Table I. Cytokine expression levels in culture supernatants of human**
2 **PBMC activated with R848.**

Cytokine	PBMC alone	PBMC + R848
IL-1 β	ND	12 ng/ml
IL-6*	ND	65 ng/ml
TNF- α	ND	11 ng/ml
IP10	0.002 ng/ml	0.028 ng/ml
IFN- λ 1	0.002 ng/ml	0.016 ng/ml
IL-8*	0.149 ng/ml	214 ng/ml
IL-12p70	ND	0.009 ng/ml
IFN- α 2	ND	0.097 ng/ml
IFN- λ 2/3	ND	ND
GM-CSF	ND	0.043 ng/ml
IFN- β	ND	0.015 ng/ml
IL-10	ND	0.283 ng/ml
IFN-γ	ND	4.2 ng/ml

3 *ND stands for “Not Detected”. All concentrations were measured on raw PBMC supernatants,*
4 *except for IL-6 and IL-8 where supernatants were diluted 12 times (*).*

5

1 **Supplementary Table II: List of RT-qPCR primers**

Primer ID	GenBank ID	Amplicon size (nt)	Sequence 5' to 3'
RPL13A-F	23521	82	AACAGCTCATGAGGCTACGG
RPL13A-R			TGGGTCTTGAGGACCTCTGT
ISG15-F	9636	117	CAGCGAACTCATCTTTGCCAG
ISG15-R			GACACCTGGAATTCGTTGCC
IFIT3-F	3437	94	AACAGATGTCCTCCGCAGTG
IFIT3-R			TGTGGATTCCAACACCCGTT
IFIT1-F	3434	84	ATGCGATCTCTGCCTATCGC
IFIT1-R			CCTGCCTTAGGGGAAGCAAA
IFIT2-F	3433	84	AATAGGACACGCTGTGGCTC
IFIT2-R			AGGCTGGCAAGAATGGAACA
IFI6-F	2537	83	GGGTGGAGGCAGGTAAGAAA
IFI6-R			GACGGCCATGAAGGTCAGG
IFI27-F	3429	106	ATCAGCAGTGACCAGTGTGG
IFI27-R			GGCCACAACCTCCTCCAATCA
IFITM3-F	10410	118	GAAGATGGTTGGCGACGTGA
IFITM3-R			CACTGGGATGACGATGAGCA
DDX58-F	23586	152	ATCCAAACCAGAGGCAGAGGAA
DDX58-R			ACTGCTTCGTCCCATGTCTGAA
MxA-F	4599	74	AAGCTGATCCGCCTCCACTT
MxA-R			TGCAATGCACCCCTGTATACC
IFIT5-F	24138	99	CACTATGGCCGCTTTCAGGA
IFIT5-R			GCGAAGGGGTGATCTGTCTT
PKR-F	5610	102	GTGGACCTCTACGCTTTGGG
PKR-R			GATGCCATCCCGTAGGTCTG
PML-F	5371	97	AGTGAGCTCAAGTGCGACAT
PML-R			CAAAGGCACTATCCTGCTCCT

2

3

Characterization of synthesized molecules

Norcerpegin. 1,1-dimethylfuro[3,4-*c*]pyridine-3,4(1*H*,5*H*)-dione was previously described in [1].

P2703. 5-cyclopropyl-1-methyl-1-phenylfuro[3,4-*c*]pyridine-3,4(1*H*,5*H*)-dione. Yield 73%, mp. 186°C. ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄) δ (ppm): 0.98 (m, 4H), 1.96 (s, 3H), 2.49 (m, 1H), 6.42 (d, *J* = 6.8 Hz, 1H), 7.37 (m, 5H), 7.88 (d, *J* = 6.9 Hz, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄) δ (ppm): 6.31, 6.38, 24.92, 31.71, 38.67, 38.94, 39.22, 39.49, 39.77, 40.05, 40.33, 95.48, 124.61, 127.81, 128.23, 139.00, 145.39, 157.07, 159.42, 165.52, 170.03. MS [ESI⁺, MeOH]: [M+H]⁺ 282.11 (32%), [M+Na]⁺ 304.09 (76%), [2M+Na]⁺ 585.20 (100%). HRMS [ESI⁺, MeOH]: calcd for C₁₇H₁₆O₃N [M+H]⁺ 282.1125 found 282.1125.

P1788. 5'-cyclopropyl-3'*H*-spiro[cyclohexane-1,1'-furo[3,4-*c*]pyridine]-3',4'(5'*H*)-dione. Yield 76%, mp. 235-236°C. ¹H NMR, (500 MHz, DMSO-*d*₆) δ (ppm): 0.88 (m, 2H), 1.02 (m, 2H), 1.36 (m, 1H), 1.57 (m, 4H), 1.72 (m, 3H), 1.89 (dt, *J* = 4.0, 13.1 Hz, 2H), 3.3 (m, 1H), 6.56 (d, *J* = 6.8 Hz, 1H), 8.01 (d, *J* = 6.8 Hz, 1H). ¹³C NMR, (125 MHz, DMSO-*d*₆) δ (ppm): 6.4 (2CH₂), 21.6 (2CH₂), 23.8, 32.1, 33.7 (2CH₂), 83.4, 98.4, 110.1, 146, 157.9, 166.3, 171.3. MS [ESI⁺, MeOH]: [M+H]⁺ 260.1 (70%), [2M+Na]⁺ 541.2(100%). El. anal. calcd. for C₁₅H₁₇NO₃ : C 69.48; H 6.61; N 5.40; Found: C 69.66; H 6.63; N 5.40.

P2512. 3'*H*-spiro[cyclohexane-1,1'-furo[3,4-*c*]pyridine]-3',4'(5'*H*)-dione was previously described in [3][4].

P1781. 5'-methyl-3'*H*-spiro[cyclohexane-1,1'-furo[3,4-*c*]pyridine]-3',4'(5'*H*)-dione, previously described in [4], was obtained from the general procedure described above.

P2705. 5'-isopropyl-3'*H*-spiro[cyclohexane-1,1'-furo[3,4-*c*]pyridine]-3',4'(5'*H*)-dione. Yield 61%, mp. 199-200°C. ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄) δ (ppm): 1.38 (m, 1H), 1.38 (d, *J* = 6.8 Hz, 6H), 1.61 (m, 2H), 1.81 (m, 7H), 5.16 (m, 1H), 6.46 (d, *J* = 6.9 Hz, 1H), 8.03 (d, *J* = 6.9 Hz, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄) δ (ppm): 21.29, 21.36, 23.84, 33.96, 45.85, 82.33, 95.46, 110.40, 141.67, 155.83, 165.31, 169.92. HRMS [ESI⁺, MeOH]: calcd for C₁₅H₂₀O₃N [M+H]⁺ 262.1438 found 262.1439.

P2707. 5'-cyclobutyl-3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridine]-3',4'(5'H)-dione. Yield 59%, mp. 214-215°C. ¹H NMR, (500 MHz, DMSO-d₆) δ (ppm): 1.37 (m, 1H), 1.57 (m, 4H), 1.74 (m, 5H), 1.90 (m, 2H), 2.26 (m, 2H), 2.34 (m, 2H), 5.0 (m, J = 8.6 Hz, 1H), 6.65 (d, J = 6.8 Hz, 1H), 8.23 (d, J = 6.8 Hz, 1H). ¹³C NMR, (125 MHz, DMSO-d₆) δ (ppm): 14.3, 21.6 (2CH₂), 23.8, 29.3 (2CH₂), 33.7 (2CH₂), 50.8, 83.4, 98.7, 109.9, 143.5, 156.7, 166.4, 171.1. HRMS [ESI⁺, MeOH]: calcd for C₁₆H₂₀O₃N [M+H]⁺ 274.1438 found 274.1440.

P1792. 5'-cyclopentyl-3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridine]-3',4'(5'H)-dione. Yield 86%, mp. 233°C. ¹H NMR, (500 MHz, DMSO-d₆) δ (ppm): 1.36 (m, 1H), 1.57 (m, 4H), 1.65 (m, 3H), 1.71 (m, 4H), 1.83 (m, 2H), 1.9 (m, 2H), 2.02 (m, 2H), 5.11 (m, J = 7.8 Hz, 1H), 6.64 (d, J = 6.8 Hz, 1H), 8.16 (d, J = 6.8 Hz, 1H). ¹³C NMR, (125 MHz, DMSO-d₆) δ (ppm): 21.6 (2CH₂), 23.7 (2CH₂), 23.8, 31.5 (2CH₂), 33.7 (2CH₂), 56.2, 83.3, 99.1, 109.9, 143.5, 156.8, 166.4, 170.8. HRMS [ESI⁺, MeOH]: calcd for C₁₇H₂₂O₃N [M+H]⁺ 288.1594 found 288.1600.

P1793. 5'-cyclohexyl-3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridine]-3',4'(5'H)-dione. Yield 59%, mp. > 270°C. ¹H NMR, (500 MHz, DMSO-d₆) δ (ppm): 1.21 (m, 1H), 1.40 (m, 3H), 1.58 (m, 6H), 1.73 (m, 6H), 1.84 (m, 2H), 1.89 (m, 2H), 4.72 (m, 1H), 6.64 (dd, J = 2, 6.8 Hz, 1H), 8.20 (dd, J = 2, 6.8 Hz, 1H). ¹³C NMR, (125 MHz, DMSO-d₆) δ (ppm): 21.6 (2CH₂), 23.8, 24.6, 25.4 (2CH₂), 31.5 (2CH₂), 33.7 (2CH₂), 53.6, 83.3, 98.9, 109.9, 143.3, 156.4, 166.4, 170.6. HRMS [ESI⁺, MeOH]: calcd for C₁₈H₂₄O₃N [M+H]⁺ 302.1751 found 302.1755.

P2706. 5'-(cyclopropylmethyl)-3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridine]-3',4'(5'H)-dione. Yield 67%, mp. 195-196°C. ¹H NMR (300 MHz, DMSO-d₆/CCl₄) δ (ppm): 0.50 (m, 4H), 1.25 (m, 1H), 1.41 (m, 1H), 1.77 (m, 9H), 3.82 (d, J = 7.2 Hz, 2H), 6.39 (d, J = 6.7 Hz, 1H), 8.08 (d, J = 6.7 Hz, 1H). ¹³C NMR (75 MHz, DMSO-d₆/CCl₄) δ (ppm): 170.67, 165.30, 156.27, 145.82, 110.49, 95.45, 52.34, 40.04, 39.76, 39.49, 39.21, 38.93, 34.00, 23.84, 21.35, 10.41, 3.24. HRMS [ESI⁺, MeOH]: calcd for C₁₆H₂₀O₃N [M+H]⁺ 274.1438 found 274.1439.

P2708. N-cyclopropyl-4-methyl-2-oxo-1-oxaspiro[4.5]dec-3-ene-3-carboxamide. Yield 62%, mp. 141-143°C. ¹H NMR, (500 MHz, DMSO-d₆) δ (ppm): 0.51 (m, 2H), 0.71 (m, 2H), 1.29 (m, 1H), 1.41 (m, 2H), 1.54 (m, 2H), 1.71 (m, 3H), 1.82 (m, 2H), 2.33 (s, 3H), 2.76 (m, 1H), 8.09 (s, 1H). ¹³C NMR, (125 MHz, DMSO-d₆) δ (ppm): 5.9 (2CH₂), 12.6, 21.5 (2CH₂), 22, 23.7, 31.9 (2CH₂), 87.9, 118, 161.6, 170.2, 178.3. HRMS [ESI⁺, MeOH]: calcd for C₁₄H₂₀O₃N [M+H]⁺ 250.1438 found 250.1440.

P2701. 5-cyclopropyl-1,1-dimethylfuro[3,4-c]pyridine-3,4(1H,5H)-dione. Yield 66%, mp. 224-225°C. ¹H NMR, (500 MHz, DMSO-d₆) δ (ppm): 0.89 (m, 2H), 1.03 (m, 2H), 1.53 (s, 6H), 3.33 (m, 1H), 6.58 (d, *J* = 6.8 Hz, 1H), 8.04 (d, *J* = 6.8 Hz, 1H). ¹³C NMR, (125 MHz, DMSO-d₆) δ (ppm): 6.5 (2CH₂), 25.3 (2CH₂), 32.1, 82.1, 98.2, 109.9, 146.2, 157.8, 166.2, 171.6. HRMS [ESI⁺, MeOH]: calcd for C₁₂H₁₄O₃N [M+H]⁺ 220.0968 found 220.0969.

P2702. 5-cyclopropyl-1-ethyl-1-methylfuro[3,4-c]pyridine-3,4(1H,5H)-dione. Yield 61%, mp. 158°C. ¹H NMR (300 MHz, DMSO-d₆/CCl₄) δ (ppm): 0.78 (t, *J* = 7.4 Hz, 3H), 0.91 (m, 2H), 1.10 (m, 2H), 1.53 (s, 3H), 1.91 (m, 2H), 3.36 (m, 1H), 6.38 (d, *J* = 6.8 Hz, 1H), 7.91 (d, *J* = 6.8 Hz, 1H). ¹³C NMR (75 MHz, DMSO-d₆/CCl₄) δ (ppm): 6.28, 6.38, 7.15, 23.85, 30.63, 31.63, 38.94, 39.22, 39.49, 39.77, 40.05, 95.45, 111.32, 144.94, 157.01, 165.44, 169.68. HRMS [ESI⁺, MeOH]: calcd for C₁₃H₁₆O₃N [M+H]⁺ 234.1125 found 234.1125.

P2718. 5-cyclopropyl-1,1-diethylfuro[3,4-c]pyridine-3,4(1H,5H)-dione. Yield 63%, mp. 176-178°C. ¹H NMR, (500 MHz, DMSO-d₆) δ (ppm): 0.64 (t, *J* = 7.39 Hz, 6H), 0.9 (m, 2H), 1.03 (m, 2H), 1.88 (q, *J* = 7.4 Hz, 2H), 1.94 (q, *J* = 7.4 Hz, 2H), 3.35 (tt, *J* = 4.12, 7.43 Hz, 1H), 6.48 (d, *J* = 6.8 Hz, 1H), 8.03 (d, *J* = 6.8 Hz, 1H). ¹³C NMR, (125 MHz, DMSO-d₆) δ (ppm): 5.7 (2CH₂), 21.6 (2CH₂), 24, 29.2, 36.3, 91.7, 97.2, 100.8, 143.3, 154.3, 158.4, 171.7. HRMS [ESI⁺, MeOH]: calcd for C₁₄H₁₈O₃N [M+H]⁺ 248.1281 found 248.1284.

P2717. 5'-cyclopropyl-3'H-spiro[cyclopentane-1,1'-furo[3,4-c]pyridine]-3',4'(5'H)-dione. Yield 72%, mp. 190-192°C. ¹H NMR, (500 MHz, DMSO-d₆) δ (ppm): 0.89 (m, 2H), 1.02 (m, 2H), 1.89 (m, 6H), 2.09 (m, 2H), 3.33 (m, 1H), 6.55 (d, *J* = 6.9 Hz, 1H), 8.03 (d, *J* = 6.9 Hz, 1H). ¹³C NMR, (125 MHz, DMSO-d₆) δ (ppm): 6.5 (2CH₂), 24.5 (2CH₂), 32.1, 37.9 (2CH₂), 91.8, 98.2, 110.9, 146.1, 157.5, 166.2, 169.5. MS [ESI⁺, MeOH]: [M+H]⁺ 246.11 (48%), [M+Na]⁺ 268.09 (52%), [2M+Na]⁺ 513.20 (100%). HRMS [ESI⁺, MeOH]: calcd for C₁₄H₁₆O₃N [M+H]⁺ 246.1125 found 246.1128.

References

- [1] T.H. Pham, A. Hovhannisyan, D. Bouvier, L. Tian, M. Reboud-Ravaux, G. Melikyan, M. Bouvier-Durand, A new series of N5 derivatives of the 1,1,5-trimethyl furo[3,4-c]pyridine-3,4-dione (cerpegin) selectively inhibits the post-acid activity of mammalian 20S proteasomes, *Bioorg. Med. Chem. Lett.* 22 (2012) 3822–3827. doi:10.1016/j.bmcl.2012.03.105.

- 1 [2] A. Hovhannisyan, T.H. Pham, D. Bouvier, L. Qin, G. Melikyan, M. Reboud-Ravaux, M.
2 Bouvier-Durand, C1 and N5 derivatives of cerpegin: synthesis of a new series based on
3 structure-activity relationships to optimize their inhibitory effect on 20S proteasome,
4 Bioorg. Med. Chem. Lett. 23 (2013) 2696–2703. doi:10.1016/j.bmcl.2013.02.079.
- 5 [3] A. Hovhannisyan, T.H. Pham, D. Bouvier, A. Piroyan, L. Dufau, L. Qin, Y. Cheng, G.
6 Melikyan, M. Reboud-Ravaux, M. Bouvier-Durand, New C(4)- and C(1)-derivatives of
7 furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of
8 the constitutive proteasome and its immunoisoform, Bioorg. Med. Chem. Lett. 24 (2014)
9 1571–1580. doi:10.1016/j.bmcl.2014.01.072.
- 10 [4] D. Villemin, N. Cheikh, L. Liao, N. Bar, J.-F. Lohier, J. Sopkova, N. Choukchou-Braham,
11 B. Mostefa-Kara, Two versatile routes towards Cerpegin and analogues: applications of a
12 one pot reaction to new analogues of Cerpegin, Tetrahedron. 68 (2012) 4906–4918.
13 doi:10.1016/j.tet.2012.03.057.
14

Supplementary material – NMR DATA

NMR data P1788

NMR data P1792

NMR data P1793

NMR data P2701

NMR data P2702

P2702 (1H)

P2702 (13C)

NMR data P2703

NMR data P2705

NMR data P2706

P2706 (1H)

P2706 (13C)

NMR data P2707

NMR data P2708

NMR data P2717

NMR data P2718